Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia
| Autor: | Giuseppe Papa, M. Soldani, S. Magro, G. D. Palka, T. Izzi, G. Nappi, Sante Tura, Alfonso Zaccaria, V. Rizzoli, C. Quarantelli, E. Lanzi, G. De Sandre, C. Carnevali, F. Salinas, G. Broccia, A. Cajozzo, C. A. Dinelli, L. Annino, Emma Cacciola, M. Gobbi, R. Buzzoni, A. Alberti, G. Panzacchi, E. Bajetta, Giovanna Corbelli, Luigi Gugliotta, L. Bruzzese, M. Bosisio, M. Fiacchini, Giovanni Pizzolo, P. Citarrella, F. De Cataldo, Rosario Giustolisi, T. Barbui, F. Leoni, M. Liberati, Franco Mandelli, Giuliana Alimena, A. Miliani, V. Raimondo, A. Manna, G. Lucarelli, S. Tura, Gianluigi Cetto, R Di Guglielmo, G. Guglielmi, R. Musso, F. Grignani, E. Dini, P. Ricci, A. Delsignore, S. Monjardini, A. Abbadessa, P. Di Marco, F. Salti, Francesco Lauria, A. Bonati, L. Geraci, M. Baccarani, Michele Baccarani, P. Rossi Ferrini, G. Corbelli, A. Porcellini, M. Tonato, G. Torlontano, P. Sansoni, G. Perona, A. Allegra, M. F. Martelli, R. Battista |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Cancer Research
medicine.medical_specialty Vincristine medicine.medical_treatment Splenectomy Antineoplastic Agents Blastic Phase Gastroenterology Prednisone hemic and lymphatic diseases Internal medicine medicine Humans Survival analysis Platelet Count business.industry Myeloid leukemia Arabinosyl cytosine Hematology Surgery Oncology Leukemia Myeloid Drug Therapy Combination business Busulfan medicine.drug |
| Zdroj: | Leukemia Research. 5:149-157 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/0145-2126(81)90073-4 |
| Popis: | The effect of early splenectomy and of polychemotherapy with hydroxyurea, busulfan, and alternate bimonthly courses of arabinosyl cytosine and vincristine plus prednisone, was evaluated in 139 previously untreated patients with chronic myeloid leukemia (CML), consecutively admitted to 18 hospitals from March 1973 to October 1974. Fifty-six patients were splenectomized and 83 patients were not splenectomized. Splenectomy did not influence the duration of chronic and blastic phase, and did not prolong survival. The prognosis of high risk patients was not improved. During the chronic phase, high platelet counts were more frequent in splenectomy group, and five patients developed thrombotic or thromboembolic complications, 5 to 19 months after the operation. The median survival of the whole group was 50 months, with 32 of 139 patients (actuarial proportion 30%) remaining alive 72 months after diagnosis, but the slope of the survival curve was similar to that of historical controls. The results of this trial suggests that new strategies should be developed for the therapy of CML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|